Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The 3C study (A CAMPATH, Calcineurin inhibitor reduction and Chronic allograft nephropathy trial) aims to test new ways to improve kidney transplants and make them more effective.

Kidney transplantation is a very good treatment for people whose kidneys no longer function sufficiently to keep them alive. Unfortunately, kidney transplant function inevitably declines over time. On average, after about 10 years the transplant “fails” and the recipient either receives another transplant or returns to dialysis.

All people who receive a kidney transplant need drugs to prevent their body from “rejecting” the new kidney. Standard medications to prevent rejection may also cause long-term damage to the kidney. The 3C Study is testing two new treatments which might avoid this long-term damage. No one knows which of the two treatments, if any, are better than existing medication.

The treatments being tested relate to immediate treatment after transplant, and your long term care, starting about six months after your transplant. Immediate treatment is referred to as ‘induction treatment’ and the longer term care as ‘maintenance treatment’.

Further information:

Our team


UK Blood and Transplant

Unrestricted grants from Pfizer and Novartis (see Unit's funding policy here)

Related research themes